血液科

订阅

MedSci主页 / 所有栏目 / 血液科

欧盟批准C5补体抑制剂ULTOMIRIS用于治疗阵发性睡眠性血红蛋白尿（PNH）成人患者

2019-07-04 不详 MedSci原创

C5补体Ultomiris阵发性睡眠性血红蛋白尿PNH
关注

亚力兄制药公司宣布，欧盟委员会已批准ULTOMIRIS（ravulizumab）--第一个也是唯一的长效C5补体抑制剂，每八周服用一次用于治疗高疾病活动度的阵发性睡眠性血红蛋白尿（PNH）成年患者。

亚力兄制药公司宣布，欧盟委员会已批准ULTOMIRIS（ravulizumab）--第一个也是唯一的长效C5补体抑制剂，每八周服用一次用于治疗高疾病活动度的阵发性睡眠性血红蛋白尿（PNH）成年患者。

PNH是一种极为罕见且严重的疾病，如果不及时治疗，可能会引起多种衰弱症状和并发症，包括血栓形成。当血凝块存在于血管内并减缓或阻止血液流过循环系统时，就会导致血栓的形成。严重的血栓会导致器官损伤，中风，心脏病发作和潜在的过早死亡。

欧盟委员会的批准是基于两项第三阶段研究的综合结果，这些研究最近在Blood杂志中发表。在这些研究中所有11个主要和次要终点显示，每8周使用一次ULTOMIRIS的疗效并不低于每两周服用SOLIRIS治疗的疗效。ULTOMIRIS的安全性与SOLIRIS相似。其他数据显示ULTOMIRIS提供及时且彻底的C5抑制，消除了与C5不完全抑制相关的突破性溶血。

美国食品和药物管理局（FDA）于2018年12月21日批准ULTOMIRIS用于PNH成人患者。日本厚生劳动省（MHLW）于2019年6月18日批准ULTOMIRIS治疗成人PNH 。

原始出处：


本文系梅斯医学（MedSci）原创编译整理，转载需授权！

评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1650575, encodeId=0d0a16505e5c6, content=<a href='/topic/show?id=64ae90120b4' target=_blank style='color:#2F92EE;'>#补体抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90120, encryptionId=64ae90120b4, topicName=补体抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6df24038723, createdName=yahu, createdTime=Thu Oct 03 06:00:00 CST 2019, time=2019-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852048, encodeId=0408185204884, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Feb 26 23:00:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930720, encodeId=f9611930e2044, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Fri Nov 22 04:00:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372115, encodeId=d73b3e21153d, content=国内怎么购买呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/20/dafb36f63f4241903de36c3d053babb8.jpg, createdBy=d367105945, createdName=Midas, createdTime=Sun Sep 01 19:43:09 CST 2019, time=2019-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800751, encodeId=e50d1800e5178, content=<a href='/topic/show?id=3261e3003ad' target=_blank style='color:#2F92EE;'>#睡眠性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73003, encryptionId=3261e3003ad, topicName=睡眠性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Wed Oct 09 12:00:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531367, encodeId=6bfd153136ee3, content=<a href='/topic/show?id=6f861443505' target=_blank style='color:#2F92EE;'>#PNH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14435, encryptionId=6f861443505, topicName=PNH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63a212256907, createdName=liuli5083, createdTime=Sat Jul 06 03:00:00 CST 2019, time=2019-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581164, encodeId=81741581164bc, content=<a href='/topic/show?id=89a218120dc' target=_blank style='color:#2F92EE;'>#Ultomiris#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18120, encryptionId=89a218120dc, topicName=Ultomiris)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=707d16724215, createdName=ms7474195563676018, createdTime=Sat Jul 06 03:00:00 CST 2019, time=2019-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590006, encodeId=fe841590006af, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Sat Jul 06 03:00:00 CST 2019, time=2019-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625896, encodeId=b4e4162589648, content=<a href='/topic/show?id=776e392006' target=_blank style='color:#2F92EE;'>#C5补体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3920, encryptionId=776e392006, topicName=C5补体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d50820925144, createdName=xlwang2698, createdTime=Sat Jul 06 03:00:00 CST 2019, time=2019-07-06, status=1, ipAttribution=)]
    2019-10-03 yahu

    #补体抑制剂#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1650575, encodeId=0d0a16505e5c6, content=<a href='/topic/show?id=64ae90120b4' target=_blank style='color:#2F92EE;'>#补体抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90120, encryptionId=64ae90120b4, topicName=补体抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6df24038723, createdName=yahu, createdTime=Thu Oct 03 06:00:00 CST 2019, time=2019-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852048, encodeId=0408185204884, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Feb 26 23:00:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930720, encodeId=f9611930e2044, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Fri Nov 22 04:00:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372115, encodeId=d73b3e21153d, content=国内怎么购买呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/20/dafb36f63f4241903de36c3d053babb8.jpg, createdBy=d367105945, createdName=Midas, createdTime=Sun Sep 01 19:43:09 CST 2019, time=2019-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800751, encodeId=e50d1800e5178, content=<a href='/topic/show?id=3261e3003ad' target=_blank style='color:#2F92EE;'>#睡眠性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73003, encryptionId=3261e3003ad, topicName=睡眠性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Wed Oct 09 12:00:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531367, encodeId=6bfd153136ee3, content=<a href='/topic/show?id=6f861443505' target=_blank style='color:#2F92EE;'>#PNH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14435, encryptionId=6f861443505, topicName=PNH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63a212256907, createdName=liuli5083, createdTime=Sat Jul 06 03:00:00 CST 2019, time=2019-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581164, encodeId=81741581164bc, content=<a href='/topic/show?id=89a218120dc' target=_blank style='color:#2F92EE;'>#Ultomiris#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18120, encryptionId=89a218120dc, topicName=Ultomiris)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=707d16724215, createdName=ms7474195563676018, createdTime=Sat Jul 06 03:00:00 CST 2019, time=2019-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590006, encodeId=fe841590006af, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Sat Jul 06 03:00:00 CST 2019, time=2019-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625896, encodeId=b4e4162589648, content=<a href='/topic/show?id=776e392006' target=_blank style='color:#2F92EE;'>#C5补体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3920, encryptionId=776e392006, topicName=C5补体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d50820925144, createdName=xlwang2698, createdTime=Sat Jul 06 03:00:00 CST 2019, time=2019-07-06, status=1, ipAttribution=)]
    2020-02-26 jklm09

    #抑制剂#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1650575, encodeId=0d0a16505e5c6, content=<a href='/topic/show?id=64ae90120b4' target=_blank style='color:#2F92EE;'>#补体抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90120, encryptionId=64ae90120b4, topicName=补体抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6df24038723, createdName=yahu, createdTime=Thu Oct 03 06:00:00 CST 2019, time=2019-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852048, encodeId=0408185204884, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Feb 26 23:00:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930720, encodeId=f9611930e2044, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Fri Nov 22 04:00:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372115, encodeId=d73b3e21153d, content=国内怎么购买呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/20/dafb36f63f4241903de36c3d053babb8.jpg, createdBy=d367105945, createdName=Midas, createdTime=Sun Sep 01 19:43:09 CST 2019, time=2019-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800751, encodeId=e50d1800e5178, content=<a href='/topic/show?id=3261e3003ad' target=_blank style='color:#2F92EE;'>#睡眠性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73003, encryptionId=3261e3003ad, topicName=睡眠性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Wed Oct 09 12:00:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531367, encodeId=6bfd153136ee3, content=<a href='/topic/show?id=6f861443505' target=_blank style='color:#2F92EE;'>#PNH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14435, encryptionId=6f861443505, topicName=PNH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63a212256907, createdName=liuli5083, createdTime=Sat Jul 06 03:00:00 CST 2019, time=2019-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581164, encodeId=81741581164bc, content=<a href='/topic/show?id=89a218120dc' target=_blank style='color:#2F92EE;'>#Ultomiris#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18120, encryptionId=89a218120dc, topicName=Ultomiris)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=707d16724215, createdName=ms7474195563676018, createdTime=Sat Jul 06 03:00:00 CST 2019, time=2019-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590006, encodeId=fe841590006af, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Sat Jul 06 03:00:00 CST 2019, time=2019-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625896, encodeId=b4e4162589648, content=<a href='/topic/show?id=776e392006' target=_blank style='color:#2F92EE;'>#C5补体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3920, encryptionId=776e392006, topicName=C5补体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d50820925144, createdName=xlwang2698, createdTime=Sat Jul 06 03:00:00 CST 2019, time=2019-07-06, status=1, ipAttribution=)]
    2019-11-22 smallant2002

    #miR#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1650575, encodeId=0d0a16505e5c6, content=<a href='/topic/show?id=64ae90120b4' target=_blank style='color:#2F92EE;'>#补体抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90120, encryptionId=64ae90120b4, topicName=补体抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6df24038723, createdName=yahu, createdTime=Thu Oct 03 06:00:00 CST 2019, time=2019-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852048, encodeId=0408185204884, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Feb 26 23:00:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930720, encodeId=f9611930e2044, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Fri Nov 22 04:00:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372115, encodeId=d73b3e21153d, content=国内怎么购买呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/20/dafb36f63f4241903de36c3d053babb8.jpg, createdBy=d367105945, createdName=Midas, createdTime=Sun Sep 01 19:43:09 CST 2019, time=2019-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800751, encodeId=e50d1800e5178, content=<a href='/topic/show?id=3261e3003ad' target=_blank style='color:#2F92EE;'>#睡眠性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73003, encryptionId=3261e3003ad, topicName=睡眠性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Wed Oct 09 12:00:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531367, encodeId=6bfd153136ee3, content=<a href='/topic/show?id=6f861443505' target=_blank style='color:#2F92EE;'>#PNH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14435, encryptionId=6f861443505, topicName=PNH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63a212256907, createdName=liuli5083, createdTime=Sat Jul 06 03:00:00 CST 2019, time=2019-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581164, encodeId=81741581164bc, content=<a href='/topic/show?id=89a218120dc' target=_blank style='color:#2F92EE;'>#Ultomiris#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18120, encryptionId=89a218120dc, topicName=Ultomiris)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=707d16724215, createdName=ms7474195563676018, createdTime=Sat Jul 06 03:00:00 CST 2019, time=2019-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590006, encodeId=fe841590006af, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Sat Jul 06 03:00:00 CST 2019, time=2019-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625896, encodeId=b4e4162589648, content=<a href='/topic/show?id=776e392006' target=_blank style='color:#2F92EE;'>#C5补体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3920, encryptionId=776e392006, topicName=C5补体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d50820925144, createdName=xlwang2698, createdTime=Sat Jul 06 03:00:00 CST 2019, time=2019-07-06, status=1, ipAttribution=)]
    2019-09-01 Midas

    国内怎么购买呢

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1650575, encodeId=0d0a16505e5c6, content=<a href='/topic/show?id=64ae90120b4' target=_blank style='color:#2F92EE;'>#补体抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90120, encryptionId=64ae90120b4, topicName=补体抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6df24038723, createdName=yahu, createdTime=Thu Oct 03 06:00:00 CST 2019, time=2019-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852048, encodeId=0408185204884, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Feb 26 23:00:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930720, encodeId=f9611930e2044, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Fri Nov 22 04:00:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372115, encodeId=d73b3e21153d, content=国内怎么购买呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/20/dafb36f63f4241903de36c3d053babb8.jpg, createdBy=d367105945, createdName=Midas, createdTime=Sun Sep 01 19:43:09 CST 2019, time=2019-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800751, encodeId=e50d1800e5178, content=<a href='/topic/show?id=3261e3003ad' target=_blank style='color:#2F92EE;'>#睡眠性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73003, encryptionId=3261e3003ad, topicName=睡眠性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Wed Oct 09 12:00:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531367, encodeId=6bfd153136ee3, content=<a href='/topic/show?id=6f861443505' target=_blank style='color:#2F92EE;'>#PNH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14435, encryptionId=6f861443505, topicName=PNH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63a212256907, createdName=liuli5083, createdTime=Sat Jul 06 03:00:00 CST 2019, time=2019-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581164, encodeId=81741581164bc, content=<a href='/topic/show?id=89a218120dc' target=_blank style='color:#2F92EE;'>#Ultomiris#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18120, encryptionId=89a218120dc, topicName=Ultomiris)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=707d16724215, createdName=ms7474195563676018, createdTime=Sat Jul 06 03:00:00 CST 2019, time=2019-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590006, encodeId=fe841590006af, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Sat Jul 06 03:00:00 CST 2019, time=2019-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625896, encodeId=b4e4162589648, content=<a href='/topic/show?id=776e392006' target=_blank style='color:#2F92EE;'>#C5补体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3920, encryptionId=776e392006, topicName=C5补体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d50820925144, createdName=xlwang2698, createdTime=Sat Jul 06 03:00:00 CST 2019, time=2019-07-06, status=1, ipAttribution=)]
    2019-10-09 makuansheng

    #睡眠性#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1650575, encodeId=0d0a16505e5c6, content=<a href='/topic/show?id=64ae90120b4' target=_blank style='color:#2F92EE;'>#补体抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90120, encryptionId=64ae90120b4, topicName=补体抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6df24038723, createdName=yahu, createdTime=Thu Oct 03 06:00:00 CST 2019, time=2019-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852048, encodeId=0408185204884, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Feb 26 23:00:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930720, encodeId=f9611930e2044, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Fri Nov 22 04:00:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372115, encodeId=d73b3e21153d, content=国内怎么购买呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/20/dafb36f63f4241903de36c3d053babb8.jpg, createdBy=d367105945, createdName=Midas, createdTime=Sun Sep 01 19:43:09 CST 2019, time=2019-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800751, encodeId=e50d1800e5178, content=<a href='/topic/show?id=3261e3003ad' target=_blank style='color:#2F92EE;'>#睡眠性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73003, encryptionId=3261e3003ad, topicName=睡眠性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Wed Oct 09 12:00:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531367, encodeId=6bfd153136ee3, content=<a href='/topic/show?id=6f861443505' target=_blank style='color:#2F92EE;'>#PNH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14435, encryptionId=6f861443505, topicName=PNH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63a212256907, createdName=liuli5083, createdTime=Sat Jul 06 03:00:00 CST 2019, time=2019-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581164, encodeId=81741581164bc, content=<a href='/topic/show?id=89a218120dc' target=_blank style='color:#2F92EE;'>#Ultomiris#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18120, encryptionId=89a218120dc, topicName=Ultomiris)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=707d16724215, createdName=ms7474195563676018, createdTime=Sat Jul 06 03:00:00 CST 2019, time=2019-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590006, encodeId=fe841590006af, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Sat Jul 06 03:00:00 CST 2019, time=2019-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625896, encodeId=b4e4162589648, content=<a href='/topic/show?id=776e392006' target=_blank style='color:#2F92EE;'>#C5补体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3920, encryptionId=776e392006, topicName=C5补体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d50820925144, createdName=xlwang2698, createdTime=Sat Jul 06 03:00:00 CST 2019, time=2019-07-06, status=1, ipAttribution=)]
    2019-07-06 liuli5083

    #PNH#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1650575, encodeId=0d0a16505e5c6, content=<a href='/topic/show?id=64ae90120b4' target=_blank style='color:#2F92EE;'>#补体抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90120, encryptionId=64ae90120b4, topicName=补体抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6df24038723, createdName=yahu, createdTime=Thu Oct 03 06:00:00 CST 2019, time=2019-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852048, encodeId=0408185204884, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Feb 26 23:00:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930720, encodeId=f9611930e2044, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Fri Nov 22 04:00:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372115, encodeId=d73b3e21153d, content=国内怎么购买呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/20/dafb36f63f4241903de36c3d053babb8.jpg, createdBy=d367105945, createdName=Midas, createdTime=Sun Sep 01 19:43:09 CST 2019, time=2019-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800751, encodeId=e50d1800e5178, content=<a href='/topic/show?id=3261e3003ad' target=_blank style='color:#2F92EE;'>#睡眠性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73003, encryptionId=3261e3003ad, topicName=睡眠性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Wed Oct 09 12:00:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531367, encodeId=6bfd153136ee3, content=<a href='/topic/show?id=6f861443505' target=_blank style='color:#2F92EE;'>#PNH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14435, encryptionId=6f861443505, topicName=PNH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63a212256907, createdName=liuli5083, createdTime=Sat Jul 06 03:00:00 CST 2019, time=2019-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581164, encodeId=81741581164bc, content=<a href='/topic/show?id=89a218120dc' target=_blank style='color:#2F92EE;'>#Ultomiris#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18120, encryptionId=89a218120dc, topicName=Ultomiris)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=707d16724215, createdName=ms7474195563676018, createdTime=Sat Jul 06 03:00:00 CST 2019, time=2019-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590006, encodeId=fe841590006af, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Sat Jul 06 03:00:00 CST 2019, time=2019-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625896, encodeId=b4e4162589648, content=<a href='/topic/show?id=776e392006' target=_blank style='color:#2F92EE;'>#C5补体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3920, encryptionId=776e392006, topicName=C5补体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d50820925144, createdName=xlwang2698, createdTime=Sat Jul 06 03:00:00 CST 2019, time=2019-07-06, status=1, ipAttribution=)]
    2019-07-06 ms7474195563676018

    #Ultomiris#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1650575, encodeId=0d0a16505e5c6, content=<a href='/topic/show?id=64ae90120b4' target=_blank style='color:#2F92EE;'>#补体抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90120, encryptionId=64ae90120b4, topicName=补体抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6df24038723, createdName=yahu, createdTime=Thu Oct 03 06:00:00 CST 2019, time=2019-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852048, encodeId=0408185204884, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Feb 26 23:00:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930720, encodeId=f9611930e2044, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Fri Nov 22 04:00:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372115, encodeId=d73b3e21153d, content=国内怎么购买呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/20/dafb36f63f4241903de36c3d053babb8.jpg, createdBy=d367105945, createdName=Midas, createdTime=Sun Sep 01 19:43:09 CST 2019, time=2019-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800751, encodeId=e50d1800e5178, content=<a href='/topic/show?id=3261e3003ad' target=_blank style='color:#2F92EE;'>#睡眠性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73003, encryptionId=3261e3003ad, topicName=睡眠性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Wed Oct 09 12:00:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531367, encodeId=6bfd153136ee3, content=<a href='/topic/show?id=6f861443505' target=_blank style='color:#2F92EE;'>#PNH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14435, encryptionId=6f861443505, topicName=PNH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63a212256907, createdName=liuli5083, createdTime=Sat Jul 06 03:00:00 CST 2019, time=2019-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581164, encodeId=81741581164bc, content=<a href='/topic/show?id=89a218120dc' target=_blank style='color:#2F92EE;'>#Ultomiris#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18120, encryptionId=89a218120dc, topicName=Ultomiris)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=707d16724215, createdName=ms7474195563676018, createdTime=Sat Jul 06 03:00:00 CST 2019, time=2019-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590006, encodeId=fe841590006af, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Sat Jul 06 03:00:00 CST 2019, time=2019-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625896, encodeId=b4e4162589648, content=<a href='/topic/show?id=776e392006' target=_blank style='color:#2F92EE;'>#C5补体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3920, encryptionId=776e392006, topicName=C5补体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d50820925144, createdName=xlwang2698, createdTime=Sat Jul 06 03:00:00 CST 2019, time=2019-07-06, status=1, ipAttribution=)]
    2019-07-06 chenwq14

    #欧盟批准#

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1650575, encodeId=0d0a16505e5c6, content=<a href='/topic/show?id=64ae90120b4' target=_blank style='color:#2F92EE;'>#补体抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90120, encryptionId=64ae90120b4, topicName=补体抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6df24038723, createdName=yahu, createdTime=Thu Oct 03 06:00:00 CST 2019, time=2019-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852048, encodeId=0408185204884, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Feb 26 23:00:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930720, encodeId=f9611930e2044, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Fri Nov 22 04:00:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372115, encodeId=d73b3e21153d, content=国内怎么购买呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/20/dafb36f63f4241903de36c3d053babb8.jpg, createdBy=d367105945, createdName=Midas, createdTime=Sun Sep 01 19:43:09 CST 2019, time=2019-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800751, encodeId=e50d1800e5178, content=<a href='/topic/show?id=3261e3003ad' target=_blank style='color:#2F92EE;'>#睡眠性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73003, encryptionId=3261e3003ad, topicName=睡眠性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Wed Oct 09 12:00:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531367, encodeId=6bfd153136ee3, content=<a href='/topic/show?id=6f861443505' target=_blank style='color:#2F92EE;'>#PNH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14435, encryptionId=6f861443505, topicName=PNH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63a212256907, createdName=liuli5083, createdTime=Sat Jul 06 03:00:00 CST 2019, time=2019-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581164, encodeId=81741581164bc, content=<a href='/topic/show?id=89a218120dc' target=_blank style='color:#2F92EE;'>#Ultomiris#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18120, encryptionId=89a218120dc, topicName=Ultomiris)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=707d16724215, createdName=ms7474195563676018, createdTime=Sat Jul 06 03:00:00 CST 2019, time=2019-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590006, encodeId=fe841590006af, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Sat Jul 06 03:00:00 CST 2019, time=2019-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625896, encodeId=b4e4162589648, content=<a href='/topic/show?id=776e392006' target=_blank style='color:#2F92EE;'>#C5补体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3920, encryptionId=776e392006, topicName=C5补体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d50820925144, createdName=xlwang2698, createdTime=Sat Jul 06 03:00:00 CST 2019, time=2019-07-06, status=1, ipAttribution=)]
    2019-07-06 xlwang2698

    #C5补体#

    0

相关资讯

FDA将优先审查C5补体单抗Eculizumab用于治疗视神经脊髓炎NMOSD患者

Alexion Pharmaceuticals公司今天宣布，FDA接受优先审查sBLA（ eculizumab），该公司的第一个C5补体抑制剂，用于治疗具有抗水通道蛋白-4（AQP4）自身抗体的神经脊髓炎视神经疾病（NMOSD）患者。